A side-by-side comparison of two Healthcare investors: Deerfield Management (Power Score 83/100) and Perceptive Advisors (Power Score 82/100), both ranked among the most active firms tracked in this category.
| Deerfield Management | Perceptive Advisors | |
|---|---|---|
| Power Score™ | 83/100 | 82/100 |
| Assets Managed | More than $16B (in assets as of December 2025, per the firm's own About page; the figure could not be checked against Form ADV Item 5.F) | Approximately $11B (across its strategies as of 30 June 2026, per the firm's own About page; the firm's Form ADV Item 5.F figure could not be read) |
| Founded | 1994 | 1999 |
| Headquarters | New York, NY | New York, NY |
| Sectors | Therapeutics, Medical Devices, Healthcare, Diagnostics, Digital Health, Life Sciences | Biotech, Life Sciences, Medical Devices, Diagnostics, Digital Health, Healthcare IT |
Deerfield describes itself as an investment firm dedicated to advancing healthcare through investment, intelligence and philanthropy, and says it holds a portfolio of more than two hundred private and public investments spanning therapeutics, medical devices, healthcare services, diagnostics and digital health. It states that it invests across capital structures and across company stages, from early-stage startups to mature companies, and that it offers structured finance solutions and customised financing for entrepreneurs and corporate partners in both public and private markets. Alongside the funds it runs an in-house research and data organisation: Deerfield Intelligence is described as the firm's data, technology and AI arm, and Deerfield Discovery and Development (3DC) as its internal R&D engine, taking early-stage therapeutics from discovery through preclinical proof of concept into clinical development. Deerfield also builds companies with academic and health-system partners through named discovery alliances. It is an SEC-registered investment adviser (CRD 157876, SEC file 801-73284) and files quarterly 13F reports covering listed equities, ADSs and convertible notes, so its public-market activity sits alongside its private investing rather than replacing it.
View full Deerfield Management profile →Perceptive Advisors is a life sciences investment manager registered with the SEC as an investment adviser (CRD 154703, SEC registration effective 4 October 2010). It says it runs four strategies. The Perceptive Life Sciences Fund invests globally in public and private companies developing biotechnology products, drugs, medical devices and diagnostics, with the majority of investments in publicly traded small and mid cap companies, and participates in growth rounds, crossover rounds, IPOs and public follow-ons. Credit Opportunities, launched with its first closed-end fund in 2014, lends to healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health, life sciences research and healthcare IT, and states a range of $20M to $300M per investment and approximately $3.5B of capital raised for private credit. Capital Solutions provides structured capital to later-stage and commercial-stage life sciences companies. The venture strategy, run through the Perceptive Xontogeny Venture Funds, invests primarily at seed and Series A in biotechnology, medtech, healthtech, digital health and healthcare tools and services, states investments of $10M to $50M when leading or co-leading a Series A, states over $700M across its venture funds, and says its people take board seats. The firm describes its team as scientists, technologists, molecular biologists, MDs and PhDs.
View full Perceptive Advisors profile →